Revelstoke Capital Partners, a private equity firm focused on investing in healthcare services companies, has completed fundraising for Revelstoke EPIC Fund III (EPIC III) to support the growth of Rarebreed Veterinary Partners (Rarebreed), which Revelstoke recapitalised in December 2021.
EPIC III, with $376 million of commitments, was substantially oversubscribed and is the third single-asset vehicle in Revelstoke’s EPIC Fund series, which collectively totals over $1 billion in commitments.
Since the firm’s inception in 2013, Revelstoke has raised over $3.9 billion in equity commitments and has invested in 25 platform companies and 132 add-on acquisitions.
Concurrently with the closing of EPIC III, Rarebreed completed the acquisition of Revelstoke portfolio company Vet’s Best Friend. Upon the combination with Vet’s Best Friend, Rarebreed now operates 118 hospitals in 11 states providing services spanning the full continuum of veterinary care, including general practice, urgent care, emergency and specialty.
With Revelstoke’s investment, Rarebreed is well-capitalised to pursue future growth through acquisitions, the opening of new locations and same store sales, all with a focus on increasing access to quality veterinary care.
